Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments

Hussain, Raja Rizwan; Al-Salloum, Noura; Alazwary, Naael; Saeedi, Jameelah; Howaidi, Sara; Daif, Abdulkader

doi:10.2217/cer-2016-0087

Cited by 7 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since no instrument has been designed in Iran so far to evaluate the disease-specific problems and to evaluate the feedback to health personnel in a semi-structured model of problems identification and care planning, it was crucial to develop and validate an instrument used to evaluate the important dimensions of the disease-specific problems and to provide an opportunity for giving feedback to health personnel. Different studies have previously used various questionnaires to assess the problems of patients with MS such as the measurement of fatigue using FSS scale [38]; stress, anxiety, and depression using DSAA 21 scale [39]; and physical problems using several questionnaires [12,40,41]. It was indicated that the MSPQ scale could be used to evaluate all the disease-specific problems, including physical, psychological, emotional, family, and socio -economic problems in patients with MS in a single questionnaire.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of the disease - specific problems questionnaire for patients with multiple sclerosis

Dehghani

2021

BMC Neurol

View full text Add to dashboard Cite

Background Patients with multiple sclerosis face numerous problems during their lifetime. A self-report measurement of disease - specific problems is required to be developed for patients with multiple sclerosis based on different cultural factors. Accordingly, this can advance our understanding on the disease-specific problems for care planning as well as improving coping ways and quality of life. This study aimed to develop and validate the scale of disease-specific problems of Multiple Sclerosis. Methods This was an exploratory sequential mixed method study conducted in three phases. Correspondingly, in the first phase, the concept of disease-specific problems was defined using the content analysis approach in patients with MS. In the second phase, the item pool was generated from the findings of the first phase, and in the third phase, psychometric properties of the scale, including face, content, and construct validity and reliability, were evaluated. Results After examining both validity and reliability, 28 items were developed in the final questionnaire. As well, by performing the factor analysis, five factors were revealed as follows: physical problems, psychological problems, emotional problems, family problems, and socio-economic problems. Internal consistency and stability of the questionnaire were calculated as 0.82 and 0.90, respectively, indicating an excellent reliability. Conclusion The 28-item questionnaire is valid and reliable for measurement of level of disease - specific problems in Iranian people with MS.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and validation of the disease - specific problems questionnaire for patients with multiple sclerosis

Dehghani

2021

BMC Neurol

View full text Add to dashboard Cite

show abstract

“…Some AEs that potentially indicate centrally mediated effects, such as depression and anxiety, have also been reported; however, MS patients frequently present with anxiety and depression, i.e., these have been reported in over 20% of MS patients (Marrie et al 2015 ). In several studies and 1 meta-analysis, fingolimod and other disease-modifying therapies (DMTs) for MS had no significant association with the onset of anxiety, depression, or other neuropsychiatric events (Al-Hussain et al 2017 ; Gasim et al 2018 ; Moreau et al 2017 ; Tauil et al 2018 ). In a subset of 141 African-American RRMS patients from a randomized open-label study, fingolimod (0.5 mg/day) was associated with a lower AE rate (AEs per patient-year) compared with injectable DMTs for anxiety (0.055 vs. 0.161) and depression (0.092 vs. 0.134) (Cascione et al 2018 ).…”

Section: Clinical Ae Data Suggestive Of Abuse or Dependence Potentialmentioning

confidence: 99%

Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data

Schoedel¹,

Kolly

Gardin

et al. 2021

Psychopharmacology

View full text Add to dashboard Cite

Abuse and misuse of prescription drugs remains an ongoing concern in the USA and worldwide; thus, all centrally active new drugs must be assessed for abuse and dependence potential. Sphingosine-1-phosphate (S1P) receptor modulators are used primarily in the treatment of multiple sclerosis. Among the new S1P receptor modulators, siponimod, ozanimod, and ponesimod have recently been approved in the USA, European Union (EU), and other countries. This review of literature and other public data has been undertaken to assess the potential for abuse of S1P receptor modulators, including ozanimod, siponimod, ponesimod, and fingolimod, as well as several similar compounds in development. The S1P receptor modulators have not shown chemical or pharmacological similarity to known drugs of abuse; have not shown abuse or dependence potential in animal models for subjective effects, reinforcement, or physical dependence; and do not have adverse event profiles demonstrating effects of interest to individuals who abuse drugs (such as sedative, stimulant, mood-elevating, or hallucinogenic effects). In addition, no reports of actual abuse, misuse, or dependence were identified in the scientific literature for fingolimod, which has been on the market since 2010 (USA) and 2011 (EU). Overall, the data suggest that S1P receptor modulators are not associated with significant potential for abuse or dependence, consistent with their unscheduled status in the USA and internationally.

show abstract

“…39 The issues associated with beta Interferon-1B injection are suggested to be responsible for inducing anxiety and stress in MS patients. 40 Depression and fatigue are other common symptoms facing MS patients; however, symptomatic management might increase patients' adherence to beta Interferon-1B treatment. 40 For decades, beta Interferon-1B treatment has proved to be effective in the management of relapsing MS, and it has been used in several clinical trials as a reference treatment to test the efficacy of newer MS DMTs.…”

Section: Teriflunomidementioning

confidence: 99%

Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis

Bazzari¹

2018

SRP

View full text Add to dashboard Cite

Multiple sclerosis is an autoimmune disease that targets the central nervous system and exposes the patients to a higher risk of various disabilities that impair their normal daily life activities. Different approaches take a part in the management of multiple sclerosis, in which pharmacological drug therapy is the corner stone and the central player in the treatment of multiple sclerosis. The pharmacological therapy can be categorized into; disease modifying therapies, symptomatic treatments, and relapse management. The discussed disease modifying therapies include; alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, natalizumab, teriflunomide and beta Interferon-1B, that have been found to share a characteristic feature of altering the immune system baseline functions in order to limit multiple sclerosis complications and deaccelerate its progression. The frequently occurring symptoms of multiple sclerosis are; depression, fatigue, general pain, spasticity, muscle spasm and other symptoms, that need to be carefully managed. Patients with multiple sclerosis face "on and off" episodes of aggravated symptoms known as a relapse that may last for days, weeks or even months. The National Institute for Health and Care Excellence guidelines have recommended the use of high corticosteroid doses as the gold-standard practice in managing a relapse episode. This review article will provide an overview of the different pharmacological therapies and their major role in the management of multiple sclerosis; via exploring the most recent published scientific evidence. In the end, a general discussion is added, focusing on the role of pharmacists and other medical experts in the clinical management of multiple sclerosis and patient support.

show abstract

Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments

Abstract: Mild anxiety was higher among interferon users, which could be due to injection anxiety reasons.

Cited by 7 publications

References 27 publications

Development and validation of the disease - specific problems questionnaire for patients with multiple sclerosis

Development and validation of the disease - specific problems questionnaire for patients with multiple sclerosis

Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data

Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis

Contact Info

Product

Resources

About